1887

Journal of General Virology header logo

Volume 86, Issue 2

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1 Free

Abstract

With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80481-0
2005-02-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/2/vir860349.html?itemId=/content/journal/jgv/10.1099/vir.0.80481-0&mimeType=html&fmt=ahah

References

  1. Anraku I., Harvey T. J., Linedale R., Gardner J., Harrich D., Suhrbier A., Khromykh A. A. 2002; Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 76:3791–3799 [CrossRef]
     [Google Scholar]
  2. Barouch D. H., Santra S., Schmitz J. E. 26 other authors 2000; Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486–492 [CrossRef]
     [Google Scholar]
  3. Barouch D. H., McKay P. F., Sumida S. M. 8 other authors 2003; Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77:8729–8735 [CrossRef]
     [Google Scholar]
  4. Been M. D., Perrotta A. T., Rosenstein S. P. 1992; Secondary structure of the self-cleaving RNA of hepatitis delta virus: applications to catalytic RNA design. Biochemistry 31:11843–11852 [CrossRef]
     [Google Scholar]
  5. Berglund P., Smerdou C., Fleeton M. N., Tubulekas I., Liljestrom P. 1998; Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16:562–565 [CrossRef]
     [Google Scholar]
  6. Berglund P., Fleeton M. N., Smerdou C., Liljestrom P. 1999; Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17:497–507 [CrossRef]
     [Google Scholar]
  7. Chen D., Endres R., Maa Y. F., Kensil C. R., Whitaker-Dowling P., Trichel A., Youngner J. S., Payne L. G. 2003; Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21:2830–2836 [CrossRef]
     [Google Scholar]
  8. Cranenburgh R. M., Hanak J. A., Williams S. G., Sherratt D. J. 2001; Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29:E26 [CrossRef]
     [Google Scholar]
  9. Dubensky T. W. Jr, Driver D. A., Polo J. M. 9 other authors 1996; Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 70:508–519
     [Google Scholar]
  10. Fleeton M. N., Chen M., Berglund P., Rhodes G., Parker S. E., Murphy M., Atkins G. J., Liljestrom P. 2001; Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183:1395–1398 [CrossRef]
     [Google Scholar]
  11. Hanke T., McMichael A. J. 2000; Design and construction of an experimental HIV-1 vaccine for a year – 2000 clinical trial in Kenya. Nat Med 6:951–955 [CrossRef]
     [Google Scholar]
  12. Hanke T., Schneider J., Gilbert S. C., Hill A. V., McMichael A. 1998; DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum : immunogenicity in mice. Vaccine 16:426–435 [CrossRef]
     [Google Scholar]
  13. Hanke T., Barnfield C., Wee E. G., Agren L., Samuel R. V., Larke N., Liljestrom P. 2003; Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84:361–368 [CrossRef]
     [Google Scholar]
  14. Hariharan M. J., Driver D. A., Townsend K. 11 other authors 1998; DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72:950–958
     [Google Scholar]
  15. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. 2004; mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279:12542–12550 [CrossRef]
     [Google Scholar]
  16. Karlsson G. B., Liljestrom P. 2004; Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol Biol 246:543–557
     [Google Scholar]
  17. Kirman J. R., Turon T., Su H., Li A., Kraus C., Polo J. M., Belisle J., Morris S., Seder R. A. 2003; Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71:575–579 [CrossRef]
     [Google Scholar]
  18. Leitner W. W., Ying H., Driver D. A., Dubensky T. W., Restifo N. P. 2000; Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51–55
     [Google Scholar]
  19. Leitner W. W., Hwang L. N., deVeer M. J., Zhou A., Silverman R. H., Williams B. R., Dubensky T. W., Ying H., Restifo N. P. 2003; Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9:33–39
     [Google Scholar]
  20. Leitner W. W., Hwang L. N., Bergmann-Leitner E. S., Finkelstein S. E., Frank S., Restifo N. P. 2004; Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22:1537–1544 [CrossRef]
     [Google Scholar]
  21. McKeever U., Barman S., Hao T., Chambers P., Song S., Lunsford L., Hsu Y.-Y., Roy K., Hedley M. L. 2002; Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 20:1524–1531 [CrossRef]
     [Google Scholar]
  22. Morris-Downes M. M., Phenix K. V., Smyth J., Sheahan B. J., Lileqvist S., Mooney D. A., Liljestrom P., Todd D., Atkins G. J. 2001a; Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19:1978–1988 [CrossRef]
     [Google Scholar]
  23. Morris-Downes M. M., Sheahan B. J., Fleeton M. N., Liljestrom P., Reid H. W., Atkins G. J. 2001b; A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine 19:3877–3884 [CrossRef]
     [Google Scholar]
  24. Mossman S. P., Bex F., Berglund P. 11 other authors 1996; Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 70:1953–1960
     [Google Scholar]
  25. Mwau M., Cebere I., Sutton J. 16 other authors 2004; A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85:911–919 [CrossRef]
     [Google Scholar]
  26. Perrotta A. T., Been M. D. 1991; A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350:434–436 [CrossRef]
     [Google Scholar]
  27. Racanelli V., Behrens S. E., Aliberti J., Rehermann B. 2004; Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity 20:47–58 [CrossRef]
     [Google Scholar]
  28. SenGupta D., Norris P. J., Suscovich T. J. 10 other authors 2004; Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol 173:1987–1993 [CrossRef]
     [Google Scholar]
  29. Shi Y., Evans J. E., Rock K. L. 2003; Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521 [CrossRef]
     [Google Scholar]
  30. Takahashi H., Cohen J., Hosmalin A. 7 other authors 1988; An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 85:3105–3109 [CrossRef]
     [Google Scholar]
  31. Williams S. G., Cranenburgh R. M., Weiss A. M., Wrighton C. J., Sherratt D. J., Hanak J. A. 1998; Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26:2120–2124 [CrossRef]
     [Google Scholar]
  32. Yamanaka R., Xanthopoulos K. G. 2004; Development of improved Sindbis virus-based DNA expression vector. DNA Cell Biol 23:75–80 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80481-0
Loading
Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1
J. Gen. Virol. 86, 349 (2005); https://doi.org/10.1099/vir.0.80481-0
/content/journal/jgv/10.1099/vir.0.80481-0
/content/journal/jgv/10.1099/vir.0.80481-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error